نتایج جستجو برای: acromegaly
تعداد نتایج: 2966 فیلتر نتایج به سال:
BACKGROUND A functional pituitary adenoma can produce multiple anterior-pituitary hormones, such as growth hormone (GH) -producing adenomas (GHoma) with prolactin or thyrotropin stimulating hormone production in the same lineage. However, it is very rare that acromegaly shows subclinical Cushing's disease (SCD) beyond the lineage. Here we describe the involvement of intratumoral coexistence wit...
HANEW, K., SASAKI, A., SATO, S., SHIMIZU, Y., MURAKAMI, O. and YOSHINAGA, K. Foctors Determining the Effectiveness o f CB-154 in the Treatment o f Acromegaly. Tohoku J. exp. Med., 1983, 139 (1), 91-95 To predict the effectiveness of CB-154 treatment in patients with acromegaly plasma Gil changes induced by CB-154 treatment were compared with Gil responses to TRH or arginine tests performed befo...
Acromegaly is predominantly caused by a pituitary adenoma, which secretes an excess of GH resulting in increased IGF1 levels. Most of the GH assays used currently measure only the levels of the 22 kDa form of GH. In theory, the diagnostic sensitivity may be lower compared with the previous assays, which have used polyclonal antibodies. Many GH-secreting adenomas are plurihormonal and may co-sec...
Patients with active untreated acromegaly show mild to moderate neurocognitive disorders that are associated to chronic exposure to growth hormone (GH) and insulin-like growth factor (IGF-I) hypersecretion. However, it is unknown whether these disorders improve after controlling GH/IGF-I hypersecretion. The aim of this study was to compare neurocognitive functions of patients who successfully u...
PURPOSE Pasireotide long-acting release is a somatostatin analog that is indicated for treatment of patients with acromegaly. This analysis documents the safety of pasireotide long-acting release in patients with acromegaly enrolled in the ACCESS trial (ClinicalTrials.gov identifier: NCT01995734). METHODS ACCESS is an open-label, multicenter, single-arm, expanded-treatment protocol designed t...
BACKGROUND The common exon 3 deletion polymorphism of the growth hormone receptor (d3-GHR) is associated with disease severity in acromegaly patients. The GHR antagonist pegvisomant (PEGV) is highly effective in treating severe acromegaly. Response to PEGV treatment seems to be influenced by d3-GHR and appears to be more responsive to PEGV, although available results remain conflicting. OBJEC...
OBJECTIVE To establish the prevalence of osteoporosis, vertebral fractures (VFs), and non-VFs in acromegaly patients with long-term controlled disease and factors potentially influencing fracture risk. DESIGN Case-control study. Patients and measurements Eighty-nine patients (46% male, mean age: 58 years) were included. We studied VFs and non-VFs, bone mineral density (BMD), and markers of bo...
Acromegaly is a chronic disease caused by hypersecretion of growth hormone (GH), most frequently from a pituitary somatotropic adenoma. Its prevalence was estimated at 60–70 cases per million people, but in recent years it seems to be higher (even 86 cases per million). Approximately 3-4 new cases of acromegaly are annually diagnosed per million people. In acromegalic patients, the mortality ra...
OBJECTIVE The aim of this study was to assess flow-mediated dilatation (FMD) of the brachial artery in patients with acromegaly. SUBJECTS AND METHODS We prospectively evaluated 25 patients with acromegaly (14 females, 11 males; aged 42 +/- 12 years; growth hormone (GH) levels 34 +/- 14 ng/ml) and 27 control subjects (15 females, 12 males; aged 45 +/- 8 years; GH levels 3 +/- 1.5 ng/ml). The p...
We encountered a 58-year-old woman with acromegaly accompanied by a cortisol-secreting adrenal tumor without clinical features of hypercortisolism. The simultaneous occurrence of these two endocrinopathies in one individual is extremely rare. She was diagnosed as having diabetes mellitus 8 years ago. Afterwards, in spite of insulin therapy, her hyperglycemia could not be well controlled. Her ac...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید